Biomedicine and Chemical Sciences
2024, Volume 3, Issue 2 : 44-48 doi: https://doi.org/10.5281/zenodo.15773451
Research Article
Effect of Vitamin D and Bone Density in Patients with Chronic Hepatitis C
Rabab Murtadha Abed
DOI : https://doi.org/10.5281/zenodo.15773451
Received
Sept. 2, 2022
Revised
Feb. 21, 2024
Accepted
March 18, 2024
Published
April 1, 2024
Abstract

Hepatitis C virus (HBV) infection is a common health problem that has a worldwide distribution. Apart from the direct effect of the virus on the liver, there are many extrahepatic manifestations among which the probable effect on bone turnover associated with low bone mineral density (BMD) and deficiency of vitamin D. The aim of this study was to investigate the effects of bone mineral metabolism and vitamin D in patients with chronic hepatitis C. This study which included a total of 45 patients with chronic HBV (age range 25–50 years) and 50 healthy people were invited to participate in the present study. Attending Imam Hussein Medical City, Karbala. Biochemical tests included total serum calcium, phosphate, and creatinine and total alkaline phosphatase and vitamin D. Serum concentrations of biochemical bone markers were in the normal range for both CHC patients and controls did not differ significantly in results.

Keywords
Alkaline phosphatase
Bone mineral density
Creatinine
Hepatitis
REFERENCES
  1. Baur, K., Mertens, J. C., Schmitt, J., Iwata, R., Stieger, B., Eloranta, J. J., ... & Swiss Hepatitis C Cohort Study Group. (2012). Combined effect of 25‐OH vitamin D plasma levels and genetic V itamin DR eceptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver International, 32(4), 635-643. https://doi.org/10.1111/j.1478-3231.2011.02674.x
  2. Bitetto, D., Fabris, C., Fornasiere, E., Pipan, C., Fumolo, E., Cussigh, A., ... & Toniutto, P. (2011). Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transplant International, 24(1), 43-50. https://doi.org/10.1111/j.1432-2277.2010.01141.x
  3. Bitetto, D., Fattovich, G., Fabris, C., Ceriani, E., Falleti, E., Fornasiere, E., ... & Toniutto, P. (2011). Complementary role of vitamin D deficiency and the interleukin‐28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology, 53(4), 1118-1126. https://doi.org/10.1002/hep.24201
  4. Chen, C. H., Lin, C. L., & Kao, C. H. (2015). Relation between hepatitis C virus exposure and risk of osteoporosis: a nationwide population-based study. Medicine, 94(47), e2086. https://doi.org/10.1097/MD.0000000000002086
  5. Chen, E. Q., Shi, Y., & Tang, H. (2014). New insight of vitamin D in chronic liver diseases. Hepatobiliary & Pancreatic Diseases International, 13(6), 580-585. https://doi.org/10.1016/S1499-3872(14)60295-2
  6. Christakos, S., Dhawan, P., Verstuyf, A., Verlinden, L., & Carmeliet, G. (2016). Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiological Reviews, 96(1), 365-408. https://doi.org/10.1152/physrev.00014.2015
  7. Cosman, F., Morgan, D. C., Nieves, J. W., Shen, V., Luckey, M. M., Dempster, D. W., ... & Parisien, M. (1997). Resistance to bone resorbing effects of PTH in black women. Journal of Bone and Mineral Research, 12(6), 958-966. https://doi.org/10.1359/jbmr.1997.12.6.958
  8. Duarte, M. P., Farias, M. L. F., Coelho, H. S. M., Mendonca, L. M., Stabnov, L. M., Oliveira, M. D. C. D., ... & Oliveira, D. S. (2001). Calcium‐parathyroid hormone‐vitamin D axis and metabolic bone disease in chronic viral liver disease. Journal of Gastroenterology and Hepatology, 16(9), 1022-1027. https://doi.org/10.1046/j.1440-1746.2001.02561.x
  9. El-Maouche, D., Mehta, S. H., Sutcliffe, C. G., Higgins, Y., Torbenson, M. S., Moore, R. D., ... & Brown, T. T. (2013). Vitamin D deiciency and its relation to bone mineral density and liver ibrosis in HIV-HCV coinfection. Antiviral Therapy, 18(2), 237-242. https://doi.org/10.3851/IMP2264
  10. Hofmann, W. P., Kronenberger, B., Bojunga, J., Stamm, B., Herrmann, E., Bücker, A., ... & Sarrazin, C. (2008). Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon α and ribavirin therapy. Journal of Viral Hepatitis, 15(11), 790-796. https://doi.org/10.1111/j.1365-2893.2008.01038.x
  11. Høiberg, M., Nielsen, T. L., Wraae, K., Abrahamsen, B., Hagen, C., Andersen, M., & Brixen, K. (2007). Population-based reference values for bone mineral density in young men. Osteoporosis International, 18, 1507-1514. https://doi.org/10.1007/s00198-007-0399-8
  12. Hu, D. J., Kane, M. A., & Heymann, D. L. (1991). Transmission of HIV, hepatitis B virus, and other bloodborne pathogens in health care settings: a review of risk factors and guidelines for prevention. World Health Organization. Bulletin of the World Health Organization, 69(5), 623. https://pubmed.ncbi.nlm.nih.gov/1959164/
  13. Huang, Z., Wei, H., Cheng, C., Yang, S., Wang, J., & Liu, X. (2017). Low bone mineral density in chronic hepatitis B virus infection: A case-control study. Pakistan Journal of Medical Sciences, 33(2), 457. https://doi.org/10.12669/pjms.332.12099
  14. Khosla, S., Hassoun, A. A., Baker, B. K., Liu, F., Zein, N. N., Whyte, M. P., ... & Conover, C. A. (1998). Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. The Journal of Clinical Investigation, 101(10), 2165-2173. https://doi.org/10.1172/JCI1111
  15. Kitson, M. T., & Roberts, S. K. (2012). D-livering the message: the importance of vitamin D status in chronic liver disease. Journal of Hepatology, 57(4), 897-909. https://doi.org/10.1016/j.jhep.2012.04.033
  16. Lange, C. M., Bojunga, J., Ramos-Lopez, E., von Wagner, M., Hassler, A., Vermehren, J., ... & Sarrazin, C. (2011). Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. Journal of Hepatology, 54(5), 887-893. https://doi.org/10.1016/j.jhep.2010.08.036
  17. Mandorfer, M., Reiberger, T., Payer, B. A., Ferlitsch, A., Breitenecker, F., Aichelburg, M. C., ... & Vienna HIV & Liver Study Group. (2013). Low vitamin D levels are associated with impaired virologic response to PEGIFN+ RBV therapy in HIV–hepatitis C virus coinfected patients. Aids, 27(2), 227-232. https://doi.org/10.1097/QAD.0b013e32835aa161
  18. Necati, Y. E. N., CE, M. G., & Özgür MEHTAP, A. K. (2006). Assessment of bone metabolism and mineral density in chronic viral hepatitis. Turk J Gastroenterol, 17(4), 260-266.
  19. Petta, S., Cammà, C., Scazzone, C., Tripodo, C., Di Marco, V., Bono, A., ... & Craxí, A. (2010). Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C. Hepatology, 51(4), 1158-1167. https://doi.org/10.1002/hep.23489
  20. Rosen C. J. (2011). Clinical practice. Vitamin D insufficiency. The New England journal of medicine, 364(3), 248–254. https://doi.org/10.1056/NEJMcp1009570
  21. Schiefke, I., Fach, A., Wiedmann, M., Aretin, A. V., Schenker, E., Borte, G., ... & Moessner, J. (2005). Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World Journal of Gastroenterology: WJG, 11(12), 1843. https://doi.org/10.3748/wjg.v11.i12.1843
  22. Schwartz, K. M., & Skinner, J. A. (2008). Hepatitis C-associated osteosclerosis: a case report. Skeletal Radiology, 37(7), 679-681. https://doi.org/10.1007/s00256-008-0471-2
  23. Taksler, G. B., Cutler, D. M., Giovannucci, E., & Keating, N. L. (2015). Vitamin D deficiency in minority populations. Public Health Nutrition, 18(3), 379-391. https://doi.org/10.1017/S1368980014000457
  24. Tanaka, T., Latorre, M. R. D. O., Jaime, P. C., Florindo, A. A., Pippa, M. G. B., & Zerbini, C. A. F. (2001). Risk factors for proximal femur osteoporosis in men aged 50 years or older. Osteoporosis International, 12, 942-949. https://doi.org/10.1007/s001980170023
  25. Terrier, B., Carrat, F., Geri, G., Pol, S., Piroth, L., Halfon, P., ... & Cacoub, P. (2011). Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Journal of Hepatology, 55(4), 756-761. https://doi.org/10.1016/j.jhep.2011.01.041
  26. Trépo, E., Ouziel, R., Pradat, P., Momozawa, Y., Quertinmont, E., Gervy, C., ... & Moreno, C. (2013). Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. Journal of Hepatology, 59(2), 344-350. https://doi.org/10.1016/j.jhep.2013.03.024
  27. Yokoyama, S., Takahashi, S., Kawakami, Y., Hayes, C. N., Kohno, H., Kohno, H., ... & Chayama, K. (2014). Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. Journal of Viral Hepatitis, 21(5), 348-356. https://doi.org/10.1111/jvh.12146
Recommended Articles
Original Article Open Access
A FRAMEWORK OF MONOCLONAL ANTIBODIES AND RELATED PRODUCTION ENGINEERING
Navneet Kumar Verma
2025, Volume 4, Issue 4 : 26-34
Loading Image... Download PDF
Research Article Open Access
Investigation of Tritrichomonas Foetus in Cattle Using Different Methods in Basrah City – Iraq
Muntaha A. H. Nasir , 
Al-Idreesi S.R. , 
Wasfi A. Al-Masoudi
2023, Volume 2, Issue 1 : 39-43
DOI: https://doi.org/10.48112/bcs.v2i1.334
Loading Image... Download PDF
Research Article Open Access
The Role of Vitamin D and Zinc In Facing COVID-19 Injury
Yazi Abdullah Jassima
2022, Volume 1, Issue 1 : 6-10
DOI: https://doi.org/10.48112/bcs.v1i1.76
Loading Image... Download PDF
Research Article Open Access
Design and Synthesis Ligands Tetradents Substituted with Halogenes in α- Position and Conjugation with Riboflavin (Bioconjugates)
Nasser Thallaj
2022, Volume 1, Issue 2 : 47-56
DOI: https://doi.org/10.48112/bcs.v1i2.85
Loading Image... Download PDF
Biomedicine and Chemical Sciences journal thumbnail
Volume 3, Issue 2
Downloads
pdf Download PDF xml Download XML
Citations
2 Views
0 Downloads
Share this article
Share icon
Share on Facebook Share on LinkedIn
Share on Twitter
License
Copyright (c) Biomedicine and Chemical Sciences
Creative Commons Attribution License Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
Biomed. Chem. Sci. open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Biomedicine and Chemical Sciences Logo
Biomedicine and Chemical Sciences
About Us
Biomedicine and Chemical Sciences (BCS), an international journal, publishes double blind peer-reviewed full-length, original papers, reviews or letters. BCS covers the latest developments in various fields of biomedicine such as cardiology, immunology, genetics, environmental health, neurology, oncology and toxicology
Support
visit www.bcsjournal.org
Follow Us
facebook twitter linkedin mendeley research-gate
© Copyright Biomedicine and Chemical Sciences (BCS). All Rights Reserved.